AFAP1L1 and soft tissue sarcoma: Considering that Sp3 is expressed at higher levels in soft tissue sarcomas and transactivates the AFAP1L1 gene, targeting Sp3 could be a powerful approach to treating advanced soft tissue sarcomas.